Surgical Complexity and Outcome of Patients Undergoing Re-do Aortic Valve Surgery.


Journal

Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219

Informations de publication

Date de publication:
2020
Historique:
received: 15 11 2019
revised: 28 01 2020
accepted: 17 02 2020
entrez: 24 3 2020
pubmed: 24 3 2020
medline: 24 3 2020
Statut: epublish

Résumé

Re-do aortic valve surgery carries a higher mortality and morbidity compared with first time aortic valve replacement (AVR) and often requires concomitant complex procedures. Transcatheter aortic valve replacement (TAVR) is an option for selective patients. The aim of this study is to present our experience with re-do aortic valve procedures and give an insight into the characteristics of these patients and their outcomes. Retrospective review of 80 consecutive re-do aortic valve procedures. Mean patients' age was 51.80±18.73 years. Aortic regurgitation (AR) was present in 51 (65.4%) patients and aortic stenosis (AS) in 38 (48.7%). Indications for reoperation were: infective endocarditis (IE) (23.8%), bioprosthetic degeneration (12.5%), mechanical valve dysfunction (5%), paravalvular leak (6.2%), patient-prosthesis mismatch (3.8%), native valve disease (25%), aortic aneurysm, pseudoaneurysm and dissection (35%), aortic root/homograft degeneration (27.5%). Forty-one (51.2%) patients underwent re-do AVR, 39 (48.8%) re-do complex aortic valve surgery (28 root, 23 ascending aorta and 6 hemiarch procedures) and 37.5% concomitant procedures. A bioprosthesis was implanted in 43.8%, a mechanical valve in 37.5%, a composite graft in 2.5%, a Biovalsalva graft in 6.2% and a homograft in 10% of patients. In-hospital mortality was 3.8% and incidence of major complications was low. A significant proportion of patients were young (61%<60 y), required complex aortic procedures (49%) or presented with contraindications for TAVR (mechanical valve, AR, IE, proximal aortic disease, need for concomitant surgery). Re-do aortic surgery remains the only treatment for such challenging cases and can be performed with acceptable mortality and morbidity in a specialised aortic centre.

Identifiants

pubmed: 32201590
doi: 10.1136/openhrt-2019-001209
pii: openhrt-2019-001209
pmc: PMC7076261
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e001209

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Ann Thorac Surg. 2010 Aug;90(2):555-60
pubmed: 20667349
J Thorac Cardiovasc Surg. 2008 Feb;135(2):316-23, 323.e1-6
pubmed: 18242260
Ann Thorac Surg. 2011 Sep;92(3):898-903
pubmed: 21871275
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
Ann Thorac Surg. 2012 Sep;94(3):778-84
pubmed: 22818963
Ann Thorac Surg. 2015 May;99(5):1601-8; discussion 1608-9
pubmed: 25754965
PLoS One. 2013;8(3):e57713
pubmed: 23469220
Eur J Cardiothorac Surg. 2017 Feb 1;51(2):347-353
pubmed: 28186293
Eur J Cardiothorac Surg. 2018 Mar 1;53(3):495-504
pubmed: 29029105
Interact Cardiovasc Thorac Surg. 2012 Jul;15(1):63-8
pubmed: 22493099
Ann Thorac Surg. 2018 May;105(5):1322-1329
pubmed: 29253463
Eur J Cardiothorac Surg. 2015 Feb;47(2):269-80; discussion 280
pubmed: 24686001
Eur J Cardiothorac Surg. 2015 May;47(5):819-23
pubmed: 25009210
Ann Thorac Surg. 2015 Oct;100(4):1298-304; discussion 1304
pubmed: 26209480

Auteurs

Renata Greco (R)

Department of Cardiothoracic Surgery, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Mirko Muretti (M)

Department of Cardiothoracic Surgery, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Jasmina Djordjevic (J)

Department of Cardiothoracic Surgery, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Xu Yu Jin (XY)

Department of Cardiac Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Nulfield Division of Clinical Lab Sciences, Oxford University, Oxford, UK.

Elaine Hill (E)

Department of Cardiothoracic Anaesthesia, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Maurizio Renna (M)

Department of Cardiothoracic Anaesthesia, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Mario Petrou (M)

Department of Cardiothoracic Surgery, Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH